Dacarbazine

• CAT Number: A000760
• CAS Number: 4342-03-4
• Molecular Formula: C6H10N6O
• Molecular Weight: 182.18
• Purity: ≥95%
• Synonyms: 1H-imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-dacarbazine (unspecified geometry).
• Target: DNA Synthesis
• Solubility: >2.3mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 4-(dimethylaminodiazenyl)-1H-imidazole-5-carboxamide
• InChI: 1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3,11H,1-2H3,(H2,7,13)/b10-6+
• InChIKey: OMJKFYKNWZZKTK-UXBLZVDNSA-N
• SMILES: CN(C)NN=C1C(=NC=N1)C(=O)N

Dacarbazine(CAS: 4342-03-4) is a monocarboxylic acid amide that is 1H-imidazole-4-carboxamide which is substituted at position 5 by a 3,3-dimethyltriaz-1-en-1-yl group. It is used for the treatment of metastatic malignant melanoma, and in combination with other drugs for the treatment of Hodgkin's disease and soft-tissue sarcoma. It has a role as an antineoplastic agent, an alkylating agent, a prodrug and a carcinogenic agent. It is a monocarboxylic acid amide, a member of imidazoles and a triazene derivative.

Reference

1: Grob JJ, Mortier L, D/'Hondt L, Grange F, Baurain JF, Dréno B, Lebbe C, Robert C, Dompmartin A, Neyns B, Gillet M, Louahed J, Jarnjak S, Lehmann FF. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO Open. 2017 Nov 14;2(5):e000203. doi: 10.1136/esmoopen-2017-000203. eCollection 2017. PubMed PMID: 29177094; PubMed Central PMCID: PMC5687540.
2: Ugurel S, Loquai C, Terheyden P, Schadendorf D, Richtig E, Utikal J, Gutzmer R, Rass K, Sunderkötter C, Stein A, Fluck M, Kaatz M, Trefzer U, Kähler K, Stadler R, Berking C, Höller C, Kerschke L, Edler L, Kopp-Schneider A, Becker JC. Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. Oncotarget. 2017 Jun 27;8(44):76029-76043. doi: 10.18632/oncotarget.18635. eCollection 2017 Sep 29. PubMed PMID: 29100289; PubMed Central PMCID: PMC5652683.
3: Schinzari G, Rossi E, Cassano A, Dadduzio V, Quirino M, Pagliara M, Blasi MA, Barone C. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study. Melanoma Res. 2017 Dec;27(6):591-595. doi: 10.1097/CMR.0000000000000401. PubMed PMID: 29076951.
4: Friedberg JW, Forero-Torres A, Bordoni RE, Cline VJM, Patel Donnelly D, Flynn PJ, Olsen G, Chen R, Fong A, Wang Y, Yasenchak CA. Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. Blood. 2017 Oct 16. pii: blood-2017-06-787200. doi: 10.1182/blood-2017-06-787200. [Epub ahead of print] PubMed PMID: 29038340.
5: Tanaka R, Goshima F, Esaki S, Sato Y, Murata T, Nishiyama Y, Watanabe D, Kimura H. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model. Am J Cancer Res. 2017 Aug 1;7(8):1693-1703. eCollection 2017. PubMed PMID: 28861325; PubMed Central PMCID: PMC5574941.